• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Restenosis - Pipeline Review, Q2 2011 - Product Image

Restenosis - Pipeline Review, Q2 2011

  • ID: 1801447
  • April 2011
  • 55 pages
  • Global Markets Direct

Restenosis - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Restenosis - Pipeline Review, Q2 2011', provides an overview of the Restenosis therapeutic pipeline. This report provides information on the therapeutic development for Restenosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Restenosis. 'Restenosis - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Restenosis.
- A review of the Restenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restenosis Overview
Therapeutics Development
An Overview of Pipeline Products for Restenosis
Restenosis Therapeutics under Development by Companies
Restenosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Restenosis Therapeutics - Products under Development by Companies
Restenosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Restenosis Therapeutics Development
AVI BioPharma Inc.
Novogen Limited
Bio3 Research S.r.l
AnGes MG, Inc.
CytoTools AG
Angelini Group
Pervasis Therapeutics, Inc.
AIM Therapeutics Inc.
ChemoCentryx, Inc.
Kemin Industries, Inc.
XBiotech USA, Inc.
Restenosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Resten-NG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIMGB1 Antagonists Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NV-27 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM1101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMW 02Ap - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AIM-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NFkB Decoy Oligodeoxynucleotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PVS-10200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCX140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bindarit - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CV-18C3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Restenosis Therapeutics – Drug Profile Updates
Restenosis Therapeutics - Discontinued Products
Restenosis - Featured News
Apr 07, 2010: Pervasis Starts Second Clinical Program Targeting Peripheral Arterial Disease
Mar 22, 2010: ChemoCentryx Announces Phase II Clinical Trial of CCX140 For Type 2 Diabetes And Vascular Restenosis
Jan 29, 2010: Bindarit A MCP-1/CCL2 Production Inhibitor
Apr 15, 2009: AnGes MG Receives Japanese Substance Patent For NF-kB Decoy Oligonucleotide
Mar 17, 2008: BioSyntech Announces Positive Preliminary Interim Data For BST-CarGel Clinical Trial
Apr 10, 2007: Samaritan Announces The Granting Of European Patent For New Type Of Cardiovascular Plaque Clearing Drug SP-1000
Nov 10, 2004: AVI BioPharma Announces Results Of Phase II Clinical Trial Resten-NG .
Sep 18, 2003: AVI BioPharma Reports Positive Phase II Clinical Results In Restenosis.
Jul 19, 2003: AVI Begins Phase II Study Of Resten-NG In Restenosis.
Nov 16, 1999: AVI BioPharma Files IND Application For Resten-NG.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Restenosis, Q2 2011
Products under Development for Restenosis – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
AVI BioPharma Inc., 2011
Novogen Limited, 2011
Bio3 Research S.r.l, 2011
AnGes MG, Inc., 2011
CytoTools AG, 2011
Angelini Group, 2011
Pervasis Therapeutics, Inc., 2011
AIM Therapeutics Inc., 2011
ChemoCentryx, Inc., 2011
Kemin Industries, Inc., 2011
XBiotech USA, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Restenosis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Restenosis, Q2 2011
Products under Development for Restenosis – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos